Currently predicting for Tue, 28 May 2024

Trading levels for KNSA

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 19.69 3.36 %
R2 19.50 2.38 %
R1 19.39 1.77 %
Current price: 19.05
Support S1 19.01 -0.195 %
S2 18.90 -0.80 %
S3 18.71 -1.78 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 20.19 5.98 %
R2 19.99 4.93 %
R1 19.97 4.83 %
Current price 19.05
Support S1 18.72 -1.73%
S2 17.68 -7.19%
S3 17.61 -7.56%

KNSA Predictions History

11 months ago
AlexVel predicted that KNSA for 2023-06-14 is going $15.78 (-4.25%)

11 months ago
PredictionBot.Kathy predicted that KNSA for 2023-06-14 is going $15.75 (-4.44%)

11 months ago
PredictionBot.Warren predicted that KNSA for 2023-06-14 is going $15.84 (-3.87%)

11 months ago
JS predicted that KNSA for 2023-06-14 is going $15.78 (-4.25%)

11 months ago
JS predicted that KNSA for 2023-05-30 is going $14.16 (3.58%)

11 months ago
PredictionBot.Kathy predicted that KNSA for 2023-05-30 is going $13.80 (0.95%)

11 months ago
PredictionBot.Warren predicted that KNSA for 2023-05-30 is going $13.90 (1.69%)

1 year ago
thichthientri2020.334159 predicted that KNSA for 2022-08-08 is going

Rank:

3 years ago
JS predicted that KNSA for 2021-03-22 is going $20.03 (-0.55%)

Click to get the best stock tips daily for free!

About Kiniksa Pharmaceuticals Ltd. Class A

Kiniksa Pharmaceuticals Ltd. Class A Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclo... KNSA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT